Celebrating Pork: The Dubious Success of the Medicare Drug Benefit Health Insurance for the Elderly
Projected costs for Medicare Part D have been revised downward, causing some analysts to claim that the program has proven itself a success. This report explores the factors behind the lower cost projections and reaches far different conclusions. It finds two main reasons: 1) a slowdown in the rate of growth in drug prices that preceded the introduction of the benefit; and 2) fewer people are expected to enroll in the program. The report recommends changes to the program that could save $30 billion a year.
|Date of creation:||Mar 2007|
|Date of revision:|
|Contact details of provider:|| Postal: 1611 Connecticut Ave, NW Suite 400, Washington, DC 20009|
Phone: (202) 293-5380
Fax: (202) 588 1356
Web page: http://www.cepr.net/
More information through EDIRC
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Dean Baker, 2007. "Stagnation in the Drug Development Process: Are Patents the Problem?," CEPR Reports and Issue Briefs 2007-07, Center for Economic and Policy Research (CEPR).
When requesting a correction, please mention this item's handle: RePEc:epo:papers:2007-08. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ()
If references are entirely missing, you can add them using this form.